Chronic Inducible Urticaria

Dermatology
4
Pipeline Programs
3
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 1 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Celldex Therapeutics
2 programs
1
1
BarzolvolimabPhase 3Monoclonal Antibody1 trial
barzolvolimabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT05405660Completed196Est. Sep 2025
NCT07266402Recruiting240Est. Oct 2028
Blueprint Medicines
Blueprint MedicinesMA - Cambridge
1 program
1
BLU-808Phase 21 trial
Active Trials
NCT06931405Recruiting105Est. Dec 2026
Jasper Therapeutics
Jasper TherapeuticsREDWOOD CITY, CA
1 program
1
BriquilimabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT06353971TerminatedEst. Jul 2025

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
Celldex TherapeuticsBarzolvolimab
Blueprint MedicinesBLU-808
Celldex Therapeuticsbarzolvolimab
Jasper TherapeuticsBriquilimab

Clinical Trials (4)

Total enrollment: 541 patients across 4 trials

NCT07266402Celldex TherapeuticsBarzolvolimab

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

Start: Jan 2026Est. completion: Oct 2028240 patients
Phase 3Recruiting
NCT06931405Blueprint MedicinesBLU-808

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

Start: May 2025Est. completion: Dec 2026105 patients
Phase 2Recruiting
NCT05405660Celldex Therapeuticsbarzolvolimab

A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Start: Jun 2022Est. completion: Sep 2025196 patients
Phase 2Completed
NCT06353971Jasper TherapeuticsBriquilimab

A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines

Start: Mar 2024Est. completion: Jul 2025
Phase 1/2Terminated

Related Jobs in Dermatology

MSL/Senior MSL, Dermatology - Tampa, Florida

AbbVie
Remote
6h ago

(Senior) Außendienstmitarbeiter Dermatology (all genders) - Region Thüringen

AbbVie
Remote
6h ago

(Senior) Außendienstmitarbeiter Dermatology (all genders) - Region Thüringen

AbbVie
Remote
6h ago

Regional Sales Trainer - Dermatology (Central / West Regions)

AbbVie
Remote
7h ago

Regional Sales Trainer - Dermatology (Northeast / Southeast Regions)

AbbVie
Remote
7h ago

Delegado Especialista Ventas Dermatología (Inmunología)

AbbVie
Remote
11h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 541 patients
Monoclonal Antibody is the dominant modality (100% of programs)
3 companies competing in this space

Related Indications

Dermatitis, Atopic(42)Hidradenitis Suppurativa(30)Chronic Spontaneous Urticaria(21)Alopecia Areata(17)Hidradenitis Suppurativa (HS)(10)Vitiligo(9)Rosacea(6)Chronic Urticaria(5)Pruritus(5)Androgenetic Alopecia(5)